title: Tenofovir-best hope for treatment of chronic hepatitis B infection?
abstract: OBJECTIVE
  To evaluate the effectiveness of tenofovir in patients with chronic hepatitis B infection in a real life setting.
  
  
  METHODS
  We performed a retrospective analysis of data from 164 patients with chronic hepatitis B who were treated with Tenofovir. Eighty-six patients (52.4%) were naïve. Seventy-seven (46.9%) patients were previously treated with anti-viral drugs, including standard interferon (n=4), pegylated (PEG) interferon (n=14), standard interferon together with lamivudine (n=13), lamivudine alone (n=41), adefovir (n=2), lamivudine together with adefovir (n=1), and entecavir (n=2). Six patients (3.7%) had liver cirrhosis before treatment of tenofovir.
  
  
  RESULTS
  The patients who have hepatitis B viral DNA>104 copy/mL with chronic hepatitis B infection were included in the treatment of Tenofovir. Average follow up time was 30.31±14.33 months. HBV DNA negativity and alanine aminotransferase (ALT) normalization were 86.5% and 71.3%, respectively, at the last visit. Hepatitis B e-Antigen (HBeAg) seroconversion occurred in 11 (19.6%) out of 164 patients. During the follow-up period, 4 (2.4%) patients developed liver cirrhosis and in 5 (3%) patients hepatocellular carcinoma (HCC) occurred out of 164 patients. HBsAg seroconversion occurred in one patient (0.6%).
  
  
  CONCLUSIONS
  Tenofovir can be used safely and successfully in those patients that were naive, experienced with immune modulators and/or antivirals, HBeAg-positive, and HBeAg-negative patients.
authors.affiliation: Department of Gastroenterology, Ankara University Faculty of Medicine, Ankara, Turkey. scoban72@yahoo.com.
authors.forename: Necati
authors.initials: N
authors.lastname: Örmeci
authors.forename: Burak
authors.initials: B
authors.lastname: Özbaş
authors.forename: Rahmet
authors.initials: R
authors.lastname: Güner
authors.forename: Hasan
authors.initials: H
authors.lastname: Özkan
authors.forename: Aysun
authors.initials: A
authors.lastname: Yalçı
authors.forename: Şahin
authors.initials: Ş
authors.lastname: Çoban
authors.forename: Abdülkadir
authors.initials: A
authors.lastname: Dökmeci
authors.forename: Çağdaş
authors.initials: Ç
authors.lastname: Kalkan
authors.forename: Hakan
authors.initials: H
authors.lastname: Akıncı
authors.forename: Osman
authors.initials: O
authors.lastname: Yüksel
authors.forename: Ömer
authors.initials: Ö
authors.lastname: Başar
authors.forename: İlhami
authors.initials: İ
authors.lastname: Yüksel
authors.forename: İsmail
authors.initials: İ
authors.lastname: Balık
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000209:etiology; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000235:genetics; D006514:Hepatitis B Surface Antigens / Q000097:blood / Q000276:immunology; D006513:Hepatitis B e Antigens / Q000097:blood / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000209:etiology; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000069078:Seroconversion / Q000187:drug effects; D000068698:Tenofovir / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D000068698:Tenofovir; D000410:Alanine Transaminase